JNJ · News · 20261019N

TALVEY Regulatory Approval Milestones

JOHNSON & JOHNSON · 2026-10-19 · Importance 34 · Surprise 42

European regulators recommended expanding TALVEY’s use in relapsed or refractory multiple myeloma. The recommendation would broaden the European indication for Johnson & Johnson’s oncology asset, subject to the applicable final regulatory process. The update adds a potential oncology growth opportunity but the report did not specify an expected approval date or quantified financial impact.